Look sorry if I bruised a few fragile egos on this board. I was looking for more poginant investment advice on this company rather than the cerebral MENSA club chair dissertation that seemed to have been going on for the last few years here. Rather than Stew leaving, I will. Can't see much happening here for sometime and unlike Liverworst whose been watching Squalamine for 9 yrs....I'm afraid my eyes have dried out just by reading this board the last week. Keep talking guys there were 500 shares traded today. Looks like a battle to keep all those shares to yourselves. Just let me know if you ever need some pumping. I'm residing in Hodge Podge Lodge. Cheers
stuartcreek: O.K. I'll keep posting, but I need to tone it down the length of my entries. Anybody investing in this is going to have to be patient for the next few months because we are going through a consolidation phase; shares are being passed from weak hands to strong hands and the price will be unpleasantly volatile (if you want bananas to fall out of a tree, you have to shake the tree).
The eye drops will work because they are just destined to based on the known science and clinical data from the IV trials. The share price will eventually reflect this. Dr. Singerman just gave a presentation entitled "Topical Squalamine for Wet AMD" at the Bascomb 10th annual angiogenesis meeting on Feb 9th and since this is his first presentation on squalamine, his interest mush have increased. Comparing squalamine eye drops to the other treatments on the horizon for wet AMD, I feel even more confident about squalamine eye drops. Squalamine eye drops are far and above better than any other treatment on the horizon due to their benign mechanism of action, method of application, low cost, and low complexity. Ohr's staff are lined up behind the shareholders based on their renumeration and if they weren't comfortable themselves projecting a huge share price for Ohr, their compensation woudn't be 90% stock options. If they thought we were any where near a high, they would have been selling. Dr. T. has been insistent in his presentations over the years that, should a partnership with Ohr on squalamine occur, it would have to be valued at over a billion dolllars
Finally in incidence of wet AMD will triple in the next 20 years. For all these reasons I have bought 260K shares over the last 18 months and holding on for a gain of 10 to 100 times my investment. But it will take time.